Investor Update On R&D Pipeline 24th August Final

Investor Update on
R&D Pipeline
24th August 2017
BSE:532872 NSE: SPARC BLOOMBERG: SPADV@IN REUTERS: SPRC.BO CIN:L73100GJ2006PLC047837

2017 - Sun Pharma Advanced Research Company Limited (SPARC). All Rights Reserved
Disclaimer
Except for the historical information contained herein, statements in this presentation and the
subsequent discussions, which include words or phrases such as will, aim, will likely
result,would, believe, may, expect, will continue, anticipate, estimate, intend, plan,
contemplate, seek to, future, objective, goal, likely, project, should, potential, will
pursue and similar expressions or variations of such expressions may constitute "forward-
looking statements". These forward-looking statements involve a number of risks, uncertainties
and other factors that could cause actual results to differ materially from those suggested by the
forward-looking statements. These risks and uncertainties include, but are not limited to our
ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory
approvals, our provisioning policies, technological changes, investment and business income,
cash flow projections, our exposure to market risks as well as other risks. Sun Pharma Advanced
Research Company Limited does not undertake any obligation to update forward-looking
statements to reflect events or circumstances after the date thereof.
2017 SPARC 2
Agenda
SPARC Strategy & Market Opportunity Key
1 Upcoming Milestones
Anil Raghavan CEO 5 Programs
Narendra Lakkad V.P. Business Development
2 Key Clinical Programs

SiuLong Yao Sr. V.P. Clinical Development &
Operations 6 Financial Update
Chetan Rajpara CFO
3 Drug Discovery Programs

Nitin Damle Sr. V.P. Discovery Biology &
Pre-clinical R&D 7 Q&A
4 Delivery System Innovations

Yashoraj Zala V.P. Formulation Development
Ajay Khopade V.P. Formulation Development
2017 SPARC 3
Agenda

Chetan Rajpara CFO


2017 SPARC 4
SPARCs R&D strategy
Innovation with balanced risk
2007 2013 2014 onwards
Delivery Systems Innovation v

Validated Biology/Novel Chemistry New Targets
Oncology | CNS | Inflammation | Ophthalmology | Dermatology
Leverage Formulation Development capabilities to pursue low hanging 505(b)(2)

opportunities
Tap validated mechanisms to create value with Medicinal Chemistry
Narrow therapeutic area focus to build deeper competencies and developmental
eco-systems
Explore novel targets and new modalities with external collaborators to de-risk
2017 SPARC 5
Our short to medium term focus
Execute well while building competencies for the future
Conclude late stage clinical programs to enhance

revenue visibility
Accelerate early stage clinical proof-of-concept
Continue to build our operating model and

partnerships
Augment our early stage pipeline
2017 SPARC 6
Focus on near term priorities
SPARC portfolio is gathering momentum
Key Milestones
Initiated: Tech transfer of ElepsiaTM XR and XelprosTM to

ElepsiaTM XR and XelprosTM
alternate manufacturing sites
Completed: Salmeterol Fluticasone DPI pivotal program,

Execution of pivotal studies
Baclofen GRS patient enrolment completed
of late stage assets
Initiated: TaclantisTM pivotal BE study
Completed: Brimonidine OD Phase 2, SDN-021 pilot PK study,

Establish Clinical PoC SUN-K0706 Phase 1 PK in healthy subjects
Initiated: SUN-K0706 Phase 1 in CML patients
New Programs entering Initiated: SUN-K0706 Phase 1 in Parkinsons Disease,

First in Human studies S1PR1 Agonist Phase 1 in healthy subjects,
SUN-597 Topical pilot study in Psoriasis
Raised: Additional capital of INR 5000 mn through

Cash Flow Management
preferential warrants
Taclantis is provisionally approved trade name for PICN by USFDA; S1PR1 = Sphingosine 1-phosphate Receptor 1 2017 SPARC 7
Our operating model is evolving
Substantial investments to make SPARC future ready
Key Priorities Talent acquisition in Discovery Biology, Clinical Development

and Regulatory Affairs
Capability Development Investments in upgrading the laboratory infrastructure and
enabling technologies
Computational and Analytical systems for enhanced

Data Analytics as a efficiencies and predictability
strategic differentiator Investments in applications, infrastructure and human capital
to build data competency for the future
Purposeful engagement with academic innovator

Strategic Partnering for communities to augment internal ideation
enhanced ideation Unique partnering proposition enabling SPARC to compete
effectively in the marketplace for ideas
Highly successful entrepreneurs with decades of experience

in life sciences industry, Investment Banking added to the
Scientific and Corporate Corporate Board
Governance
Collaboration with several accomplished scientific leaders
through portfolio/program level advisory boards
2017 SPARC 8
Long-term portfolio strategy
Focused approach and translational discipline
Highly focused program selection

Treatment resistance in select cancers
Neurodegenerative conditions with clear molecular bases
Inflammation/Auto-immune disorders
Abuse deterrence
Drug Delivery Platform development
Selective expansion to novel modalities
External validation in go/ nogo decision making
Full pursuit of assets wherever possible
2017 SPARC 9
Setting expectations
Upcoming milestones for SPARC
Brimonidine OD SDP 037

Pivotal study initiation Pivotal study
initiation
Baclofen GRS Salmeterol IND Filings

Study Fluticasone DPI 4 INDs
completion, European MAA
NDA filing & filing & Out-
Out-licensing licensing
SDN 021 Taclantis

Pilot HAL study Pivotal BE study
initiation completion
SUN K0706 SUN K0706

PD - PoC study CML - Pivotal
initiation study initiation
HAL = Human Abuse Liability; PD = Parkinsons Disease; CML = Chronic Myelogenous Leukemia; MAA = Marketing Authorization Application 2017 SPARC 10
Agenda

Chetan Rajpara CFO


2017 SPARC 11
Baclofen GRS
Development on track as planned
Recruitment completed for all Phase 3 studies
Duration of Action
Efficacy Study Safety Study
Study
Number of
285 135 375
Subjects
Status Recruitment Studies completed
completed Data under review
LPO Aug17
Data read-out in Oct17
Planned NDA filing by Q1FY19
LPO = Last Patient Out 2017 SPARC 12

Salmeterol Fluticasone Dry Powder Inhaler
Summary of pivotal studies results
Peak Inspiratory Flow (PIF) study

Mean PIF values well within the required range
All subject groups successfully able to use SPARC device
High Dose Pharmacokinetic (PK) study

Fluticasone and salmeterol PK comparable to Seretide Accuhaler PK
Low Dose Pharmacokinetic (PK) study
Fluticasone PK comparable to Seretide Accuhaler PK

Peak concentration of salmeterol higher, and did not satisfy BE criteria
Safety profile similar to that of Seretide Accuhaler
2017 SPARC 13
Next steps
Based on PIF study, High dose and Low dose PK

study data, SPARC is consulting EU regulatory
agencies to understand path forward for
approval of all 3 strengths
EU = European Union 2017 SPARC 14

TaclantisTM
Pursuing BE strategy for USA registration
Novel formulation of paclitaxel using SPARCs proprietary

Nanotecton platform technology
100000
Mean Plasma Concentration
Completed pilot BA/BE studies 10000
Data suggest possibility of BE in a Total Paclitaxel

fully powered PK study 1000
ng/ml
No unanticipated safety findings
100
Initiated pivotal BE study in Q2FY18 Free Paclitaxel

10
4 subjects randomized
1
Planned NDA filing by Q3FY19
0 2 4 6 8 10 12
Time (Hours)
Taclantis nab-paclitaxel Taclantis nab-paclitaxel
2017 SPARC 15
SUN K0706 CML
Highly selective BCRABL Inhibitor
Potent and orally bioavailable

SUN K0706 Plasma Profile
Effective against BCR-ABL and its
1000
mutants, including T315I mutation
Plasma concentration (ng/mL)

Completed Single Ascending Dose
100
(SAD) study in healthy volunteers
Orally bioavailable
PK supports once-a-day dosing 10
6 mg Fast (N=14)
Dose proportionality established
12 mg Fast (N=6)
No food effect 24 mg Fast (N=14)
1
Safe and well tolerated 0 6 12 18 24
Initiated Multiple Ascending Dose Time (Hours)
(MAD) study in CML patients

2 dose levels completed
2017 SPARC 16
SUN K0706 CML
Development status update
Plan to complete the MAD study by Q4FY18
Initiation of pivotal efficacy study by Q2FY19
2017 SPARC 17
Brimonidine OD
Improving Glaucoma patient compliance and adherence
Brimonidine is a commonly used second

line drug to treat Glaucoma
Treatment adherence with Brimonidine is

highly variable*
Patients on Brimonidine TID achieve

significantly lower adherence rates*
SPARC is developing a novel once-a-day

formulation using proprietary TearActTM
Technology
* J Glaucoma. 2011 Oct;20(8):502-8; OD = Once-a-Day, TID = Three times a day 2017 SPARC 18
Brimonidine OD
Achieves similar IOP reduction as Alphagan P TID
Proof-of-concept established in Phase 2 study in 140 Glaucoma patients

Met pre-specified clinical equivalence efficacy criteria compared to Alphagan P
TID at all time points
No new adverse events reported
Brimonidine OD Vs Alphagan P at 5 pm Timepoint
26
24 Brimonidine OD

Alphagan P
22
IOP (mm Hg)
20
18
16
14
12
10
0 14 28 42 56 84
Days
IOP = Intra Occular Presesure 2017 SPARC 19

Brimonidine OD
EoP2 meeting with US FDA & IND filing by Q3FY18
Phase 3 initiation by Q4FY18
EoP2 = End of Phase 2 2017 SPARC 20

SUN 597 Topical
Novel topical steroid for steroid responsive

dermatoses
IND opened in USA

Phase 1 vasoconstrictor assay study
completed
Initiating pilot study in psoriasis patients,
topline data expected by Q3FY18
Phase 1 healthy volunteer safety/tolerability

study planned in Q4FY18
30 day minipig toxicity study completed
Outcome from the above studies will guide

further clinical development
2017 SPARC 21
Agenda

Chetan Rajpara CFO


2017 SPARC 22
Parkinsons Disease
Growing evidence of c-Abl kinase involvement
10 mn people worldwide living with

Parkinsons Disease^
Currently available therapies provide
symptomatic relief only
No disease modifying therapy available
Expression and activation of c-Abl kinase is
observed in neuronal cells overexpressing
-Synuclein
Several proteins involved in proteosomal

degradation and autophagy are substrates
of activated c-Abl kinase
c-Abl phosphorylation of -Synuclein at

tyrosine 39 enhances -Synuclein
aggregation
^Parkinsons Disease Foundation - http://www.pdf.org/parkinson_statistics; Image adapted Nature Reviews Drug Discovery16, 371373:2017 2017 SPARC 23
SUN K0706 PD
Promising neuroprotective activity in mouse model of PD
Representative photomicrographs showing TH-immunoreactive neurons in SNPc
14
Integrated Density of TH-Immunoreactivity 25
% Area of TH-Positive Neurons
12
10 20
Int Density
8
15
% Area
6
10
4
5
2
0 0
Nave Placebo of K0706 (1 mpk) K0706 (3 mpk) K0706 (10 mpk) Nave Placebo of K0706 (1 mpk) K0706 (3 mpk) K0706 (10 mpk)
K0706 K0706
Crosses blood brain barrier

SUN K0706 prevents MPTP induced degeneration of dopaminergic neurons in
Substantia Nigra
TH = Tyrosine Hydroxylase; SNPc = Substantia Nigra Pars compacta ; MPTP= Methyl Phenyl Tetrahydropyridine 2017 SPARC 24
SUN K0706 PD
Initiated phase 1 study in Parkinsons Disease patients
Phase 1
Assessment of PK, safety and
tolerability in patients
Study ongoing; 2 cohorts completed
Phase 2
Proof of efficacy study in Parkinsons
Disease patients to be initiated
2017 SPARC 25
SCD 044
Novel highly selective S1P Receptor 1 agonist for
auto-immune disorders
Project under collaboration with Bioprojet,

France
Fingolimod is the 1st in class S1P receptor

agonist approved for Multiple Sclerosis
US$ 3.1 bn global sales in 2016*

Being non-selective modulator, Fingolimod
is associated with serious cardiac side-
effects
SCD 044 is highly selective for SIP

receptor 1 (S1PR1) over S1PR3
S1PR1 EC50 (nM)
agonists
Higher selectivity for S1PR1 is expected to
S1PR1 S1PR3 S1PR5
provide better cardiac safety profile
SCD 044 0.2 >10000 9
1
Fingolimod 1.2 1.4 4.9
*Evaluatepharma; 1. JMC, 2005, 48,5373-77; Nature 510,5867, June 2014 2017 SPARC 26
SCD 044
Comparable pre-clinical efficacy to Fingolimod
Achieves comparable lymphopenia, a

marker of efficacy, across different species
Drug Lymphopenia
SCD 044 is efficacious in animal models of
autoimmune inflammation Rat, 0.3 mg/kg Dog, 0.3 mg/kg
Desirable oral bioavailability and PK profile 24 Hrs 24 Hrs 48 Hrs

in animal species like mice, rat, dog and
SCD 044 78% 77% 77%
monkey
Fingolimod 72% 73% 75%
No cardiac side effects observed in dog
telemetry study
2017 SPARC 27
SCD 044
Completed 13 week toxicity studies in rodents

and primates
Completed safety pharmacology and preclinical

efficacy studies
IMPD filed in Europe
Phase 1 initiation by Q3FY18
IMPD = Investigational Medicinal Product Dossier 2017 SPARC 28

Agenda

Chetan Rajpara CFO


2017 SPARC 29
Prescription Opioids Abuse
IR opioids are most vulnerable
>20,000 deaths occurred in 2015 due

to prescription opioid overdose* Common routes of IR opioid abuse
100%
66% of abusers prefer IR 90%
formulations# 80%
70%
Ease of manipulation drives
60%
% abusers
preference for IR dosage forms
50%
Oral ingestion of multiple pills is the 40%
most common form of abuse^ 30%
20%
10 ADFs approved by USFDA till date 10%
None of the approved formulations 0%

Hydrocodone Oxycodone Oxymorphone Hydromorphone
have label for deterring oral multi-pill
abuse Oral Snorting Injection
* Underlying Cause of Death 1999-2015 on CDC WONDER Online Database, released December 2016; ^Postgraduate Medicine, 2016, 128:1, 85-96
# Researched Abuse, Diversion and Addiction-Related Surveillance System technical report Q3 2015. 2017 SPARC 30
SDN 021
Designed to deter multi-pill oral abuse
Delivers clinically effective dose if used as Schematic representation of

prescribed technology
Upon ingestion of multiple pills, the technology

reduces peak drug levels and slows down the
release
Deprives abuser of the desired high with
multiple pills
Technology is also designed to deter abuse by
other prevalent routes injection and snorting
Employs GRAS excipients pH modifier
pH responsive
API polymer
2017 SPARC 31
SDN 021
Lead formulation demonstrated acceptable PK characteristics
Single tablet PK data Multiple tablet PK data
Cmax blunted by ~30%

Tmax delayed
Cmax blunted by ~50%
SDN-021 fasted Ref fasted SDN-021fed Ref fed Ref fasted SDN-021 fed SDN-021 fasted
Fed state Potential to meet BE in Ingestion of multiple tablets resulted in

both AUC and Cmax optimal reduction in Cmax and delay in
Fasted state Potential to meet BE in Tmax
AUC, however Cmax was lower Manifests in potential optimal
difference in human likability study
PK data appears to be adequate for
efficacy in patients
2017 SPARC 32
SDN 021
In-vitro Category I Abuse Deterrence studies

and Pilot Human Abuse Liability (HAL)
studies planned in Q3FY18
Consultation with USFDA planned to discuss

registration pathway and Abuse Deterrence
label for oral multi-pill abuse
2017 SPARC 33
Minocycline Topical
Preclinical PoC in Acne model

Novel safer and
efficacious formulation of 1.9
minocycline for Acne
1.8 Placebo
Formulation optimized
based on successful rabbit
1.7
Right Ear Thickness (mm)

toxicity study outcome Disease
Control
Minipig toxicity study
Mean+SD
1.6
ongoing Oral
1.5 Minocycline
Pre-IND meeting planned

Clindamycin
with USFDA by Q4FY18 1.4 Gel
IND submission targeted 1.3

Propionibacterium acnes injection (Day 0) Minocycline
in Q1FY19 Treatment (day 1 to day 14) Topical
1.2
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Days
2017 SPARC 34
SDP 037
Novel BID steroid for Ocular pain and inflammation
Steroids are mainstay treatment for ocular pain

SDP 037 Reference
& inflammation Steroid
US$ 750 mn sales in USA*
Currently approved steroid eye drops are

administered 3 to 4 times per day
Marketed eye drops have hazy/milky
appearance which may cause blurring of vision
upon instillation
SPARC is developing novel formulation of an
approved steroid
BID dosing
Clear/transparent appearance
*IMS MAT Jun 2017; BID = Twice a Day 2017 SPARC 35

SDP 037
Designed with novel Micellar Technology
Uses proprietary composition of non-ionic,

cationic and anionic solubilizers to produce
unique micelles
Solubilization of steroid provides clear colorless
appearance
Polymeric stabilizer provides longer retention
and bio-adhesion
Helps retain efficacy at reduced dosing
frequency & lower drug concentrations
Patents filed
Polymer Solubilizer
Drug
2017 SPARC 36
SDP 037
Comparable pre-clinical efficacy at BID dosing and lower
drug concentration
Efficacy of SDP-037 vs. Reference Efficacy of SDP-037 vs. Reference

Steroid in rabbit model of acute uveitis Steroid in rabbit model of paracentesis
70 3
60
2.5
Total Cell count
50
PGE2 (ng/ml)
2
40
1.5
30
20 1
*** ***
10 *** 0.5 ***
0
0
PBS LPS LPS + LPS + LPS +
Disease Control SDP-037 BID Reference
Treated (Disease Vehicle SDP-037 Reference
Steroid QID
Control) BID Steroid
QID
Data were analyzed using one way ANOVA followed by Dunnetts multiple comparison testversus Disease Control, ***= p<0.001 .
LPS = Lipopolysaccharide 2017 SPARC 37

SDP 037
Pre-IND meeting with USFDA completed
IND submission by Q4FY18
Phase 3 pivotal study initiation by Q1FY19
2017 SPARC 38
Agenda

Chetan Rajpara CFO


39
Baclofen GRS
Significant commercial opportunity for once-a-day formulation
16
USA Baclofen Solid Oral Market* 900
789
Majority of physicians believe that 14 713 800
664
steady blood levels and once-a-day 12 628 700
dosing are key benefits over IR 10 495

535 600
Baclofen^ 8 9
10 500
8 400
6 7
IR Baclofen highly genericised; unit 4 5
6
300
200
volume in USA growing at 11% 2
TRx (millions) Number of tablets (millions) 100
- -
Prescription volume at 10 mn, dispensed 2012 2013 2014 2015 2016 2017
by wide spectrum of specialties
25% - 35% of prescription market is USA Baclofen TRx by Specialty (Mn)

potentially addressable
1.9
Estimated USA peak sales potential 3.3 Family Practice
~US$100 mn 1.7 Internal Medicine

Osteopathic medicine
2.3 1.1 Neurology

Other
* IMS MAT May 2017 ^ Primary research conducted through 3rd party in USA 2017 SPARC 40
TaclantisTM
Cremophor and Albumin free paclitaxel formulation
Cremophor based paclitaxel

Percentage of Patients with Documented Hypersensitivity
formulations are associated with Reactions to Paclitaxel*
hypersensitivity reactions
~12% of patients have documented

hypersensitivity reactions*
TaclantisTM eliminates the need of pre- 35% N=75

medication with corticosteroids and
anti-histamines
17% 17%
9% 9% 9%
No significant hypersensitivity 6%
reactions observed in clinical studies 0% 1-4% 5-9% 10-14% 15-19% 20-29% 30% or
with TaclantisTM higher
*Primary market research conducted through 3rd party in USA. 2017 SPARC 41
TaclantisTM
Market Opportunity
Overall paclitaxel volume sales stagnated USA patient share*

over last 2 years nab-paclitaxel Conventional Paclitaxel
Increasing penetration of novel agents

may limit the use of paclitaxel
No. of patients
37000
~ 65% paclitaxel treated patients
prescribed Cremophor based 2500
formulation* 16500
17000
Significant opportunity for conversion to 7000 7000
novel formulations like TaclantisTM Metastatic Breast Lung Cancer Pancreatic Cancer
Cancer
*Internal estimates based on IMS MAT Jun 2017 2017 SPARC 42

ICS/LABA DPI market dynamics in Europe
Total ICS/LABA Dry Powder Inhaler ICS+LABA DPI sales (US$Mn) in Europe*
market in Europe is estimated to be ~
US$ 2.5 bn* 199 133
Seretide Accuhaler has market share of

34% in ICS/LABA market 830
977
New once-a-day device products are 1160
rapidly gaining market share

147
Seretide Accuhaler generics have so

far achieved limited penetration* Budesonide + Formoterol Fluticasone furoate + Vilanterol
Beclomthasone + Formoterol Seretide
Significant price erosion of Seretide Salmeterol + Fluticasone Generics
Accuhaler
Market may see additional generics
* IMS PADDS 2016 2017 SPARC 43

Brimonidine OD
USA Glaucoma market Healthy growth trend
USA Glaucoma Market, (US$ Mn)*

Over 2.7 mn glaucoma patients in
the USA; expected to reach 4.3 mn
135 29
by 2030** 196
Glaucoma market in USA estimated 430
at US$ 2.7 bn with 35 mn

1,374
prescriptions dispensed in last year*
Rx volume growth of 4.1% CAGR

over 2012-17 520
Brimonidine is the highest

prescribed antiglaucoma drug after Prostaglandins FDCs Brimonide
Prostaglandins CAIs Beta Blockers Other Miotics
*IMS MAT Jun 2017; **National Eye Institute, US ; FDCs = Fixed dose combinations, CAIs = Carbonic anhydrase inhibitors 2017 SPARC 44
Brimonidine OD
Market acceptance of improved Brimonidine products
Brimonidine USA Sales (Mn)*
$500 $15
$422
$400 $13
$374
$400
Brimonidine initially approved as $301
$333
$8
$11
$8
Brimonidie 0.2% eye drops $300 $7 $7 $7 $9
$7
$200
Tolerability issues with 0.2% strength $5
$3
led to development of 0.15% and 0.1% $100
$1
products $ -$1
2013 2014 2016 2016 2017
Brimonidine 0.15% and 0.1% continue
0.1% / 0.15% 0.2%
to dominate market in both value and
volumes inspite of genericization of
Brimonidine 0.2% Brimonidine USA Rx (Mn)*
2.5
Differentiated once-a-day Brimonidine
2.0
formulation expected to take
TRx (Million)
1.5
meaningful market share
1.0
.5
.0
2013 2014 2016 2016 2017
0.1% / 0.15% 0.2%
*IMS MAT Jun 2017 2017 SPARC 45

SUN K0706 CML
Addressing high unmet need in treatment resistant CML
Estimated 50,000 patients are living

300 USA Prescription Volume*
with CML in USA^
253
241 234
250
~15% patients discontinue 2nd line
therapy due to adverse events# 200 196
200
Limited treatment options for
` 000
150
patients who fail two lines of
treatment 91 91
100 76
Low physician satisfaction for 62
50 63 67
available 3rd line and beyond
4 7 9 9
treatment# 1
0
2013 2014 2015 2016 2017
SUN K0706 has demonstrated Imatinib Dasatinib Nilotinib Bosutinib Ponatinib
efficacy and safety in treatment
resistant CML preclinical models
and toxicology studies
# Primary market research conducted through 3rd party. * IMS MAT June 2017. ^Internal Estimates 2017 SPARC 46
Agenda

Chetan Rajpara CFO


47
Financial Summary
(INR Mn) FY17 FY16 FY15 FY14 FY13
Total Income 1,946 1,642 1,588 1,770 889
Total Expenses 3,149 2,342 1,983 1,427 1,114
Profit / (Loss) after tax (1,203) (700) (395) 303 (225)
Liquidity Status
Cash and equivalents INR 282 mn as on 30th June 17
Delay in commercialization of XelprosTM & ElepsiaTM XR
Higher working capital need due to GST
2017 SPARC 48
Financial Summary
Expected cash outflows

Increased number of clinical programs
Higher operating expenses
Acquisition & refurbishing cost of new facility at
Savli
Expected cash inflows

Raised INR 5,000 Mn through Preferential Issue of
Warrants (25% received)
Out-licensing of Baclofen GRS if clinical studies
outcome is positive
2017 SPARC 49
Agenda

Chetan Rajpara CFO


50
R&D Pipeline
Pre- Approved
Product Indication Discovery Preclinical Phase 1 Phase 2 Phase 3
registration / Market
ElepsiaTM XR
Epilepsy
(Levetiracetam ER)
XelprosTM
Glaucoma
(Latanoprost BAK Free)
Salmeterol-Fluticasone
Asthma / COPD
DPI
Baclofen GRS Spasticity
TaclantisTM
Cancer
(PICN)
Brimonidine OD Glaucoma
SDN 021 Pain
SUN K0706 CML

Steroid Responsive
SUN 597 Topical
Dermatoses
SUN K0706 Parkinsons Disease
Minocycline Topical Acne
Autoimmune
SCD 044
Disorders
SUN K0954 CML
Ocular Pain &

SDP 037
Inflammation
2017 SPARC 51
For updates and specific queries,
please visit www.sparc.life or contact
Narendra Lakkad
Tel : +91 22 6645 5645, Ext 5607
Tel Direct : +91 22 66455607
Mobile : +91 9821510498
[email protected]
2017 Sun Pharma Advanced Research Company Limited., All Rights Reserved.
The SPARC Logo is a trademarks of Sun Pharma Advanced Research Company Ltd . In addition to Company data, data from market research agencies, Stock
Exchanges and industry publications has been used for this presentation. This material is for use during an oral presentation; it is not a complete record of the
discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media
without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of the
Company.

Investor Update On R&D Pipeline 24th August Final

Uploaded by

Copyright:

Available Formats

Investor Update On R&D Pipeline 24th August Final

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Investor Update On R&D Pipeline 24th August Final

Uploaded by

Copyright:

Available Formats

Investor Update on

BSE:532872 NSE: SPARC BLOOMBERG: SPADV@IN REUTERS: SPRC.BO CIN:L73100GJ2006PLC047837

SPARC Strategy & Market Opportunity Key

2 Key Clinical Programs

3 Drug Discovery Programs

4 Delivery System Innovations

SPARC Strategy & Market Opportunity Key

2 Key Clinical Programs

3 Drug Discovery Programs

4 Delivery System Innovations

2007 2013 2014 onwards

Delivery Systems Innovation v

Oncology | CNS | Inflammation | Ophthalmology | Dermatology

Leverage Formulation Development capabilities to pursue low hanging 505(b)(2)

Conclude late stage clinical programs to enhance

Accelerate early stage clinical proof-of-concept

Continue to build our operating model and

Augment our early stage pipeline

Initiated: Tech transfer of ElepsiaTM XR and XelprosTM to

Completed: Salmeterol Fluticasone DPI pivotal program,

Completed: Brimonidine OD Phase 2, SDN-021 pilot PK study,

New Programs entering Initiated: SUN-K0706 Phase 1 in Parkinsons Disease,

Raised: Additional capital of INR 5000 mn through

Key Priorities Talent acquisition in Discovery Biology, Clinical Development

Computational and Analytical systems for enhanced

Purposeful engagement with academic innovator

Highly successful entrepreneurs with decades of experience

Highly focused program selection

Selective expansion to novel modalities

External validation in go/ nogo decision making

Full pursuit of assets wherever possible

Brimonidine OD SDP 037

Baclofen GRS Salmeterol IND Filings

SDN 021 Taclantis

SUN K0706 SUN K0706

SPARC Strategy & Market Opportunity Key

2 Key Clinical Programs

3 Drug Discovery Programs

4 Delivery System Innovations

Recruitment completed for all Phase 3 studies

Data read-out in Oct17

Planned NDA filing by Q1FY19

LPO = Last Patient Out 2017 SPARC 12

Peak Inspiratory Flow (PIF) study

High Dose Pharmacokinetic (PK) study

Low Dose Pharmacokinetic (PK) study

Fluticasone PK comparable to Seretide Accuhaler PK

Based on PIF study, High dose and Low dose PK

EU = European Union 2017 SPARC 14

Novel formulation of paclitaxel using SPARCs proprietary

Completed pilot BA/BE studies 10000

Data suggest possibility of BE in a Total Paclitaxel

Initiated pivotal BE study in Q2FY18 Free Paclitaxel

Potent and orally bioavailable

Plasma concentration (ng/mL)

Initiated Multiple Ascending Dose Time (Hours)

(MAD) study in CML patients

Plan to complete the MAD study by Q4FY18

Initiation of pivotal efficacy study by Q2FY19